Current issues in the treatment of visceral leishmaniasis.
Bryceson
A
A
London School of Hygiene and Tropical Medicine, UK. a.bryceson@doctors.org.uk
D000666:Amphotericin B / Q000627:therapeutic use*; D000981:Antiprotozoal Agents / Q000627:therapeutic use*; D004361:Drug Tolerance; D006801:Humans; D007898:Leishmaniasis, Visceral / Q000188:drug therapy* / Q000191:economics / Q000517:prevention & control; D055502:Secondary Prevention
D000981:Antiprotozoal Agents; D000666:Amphotericin B